Jefferson City, Mo. – Missouri Attorney General Catherine Hanaway took decisive action on Monday to protect the state’s hospitals and the patients they serve. In a cease‑and‑desist letter addressed to Eli Lilly and Company, Hanaway ordered the pharmaceutical giant to stop imposing unlawful conditions on hospitals that participate in the federal 340B Drug Pricing Program.
Unlawful data‑submission demands
Hanaway’s letter cites a 2026 company policy that required every 340B‑eligible hospital to submit detailed claims data for each dispensation of any Lilly product, regardless of the care setting. When the University of Missouri Health Care (MU Health Care) refused to comply, the company allegedly cut the hospital off from 340B pricing in early July, forcing the hospital to pay higher prices for prescription drugs.
To keep patients from losing access to affordable medication, MU Health Care temporarily provided the requested data. Hanaway warned that this compliance now imposes a “heavy and unnecessary cost” on the hospital, a cost she says violates both the intent of the federal program and Missouri law.
Impact on rural communities
Hanaway emphasized that the tactics hurt Missouri’s most vulnerable areas. “Big Pharma does not get to bully Missouri hospitals or hold prescription drug prices hostage,” she said. “These tactics fall hardest on rural communities that depend on the 340B program to keep clinics open and ensure patients receive the care they need.”
The 340B program was created to allow hospitals serving low‑income patients to purchase outpatient drugs at reduced prices. By restricting a hospital’s ability to access those discounts, a drugmaker can effectively raise the cost of care for the most vulnerable Missourians.
Legal basis for the cease‑and‑desist
Hanaway’s office argues that Eli Lilly’s policy conflicts with the federal statute governing the 340B program, which does not permit manufacturers to demand exhaustive data beyond what is necessary to verify eligibility. Additionally, Missouri law prohibits practices that unduly burden hospitals operating under the program.
The Attorney General’s office is seeking compliance from Eli Lilly and is inviting any Missourian who believes they have been harmed by unfair pharmaceutical pricing to file a complaint at ago.mo.gov.
Company response pending
KCTV has reached out to Eli Lilly for comment and will update the story when a response is received.
What’s next?
Hanaway’s action signals a broader effort by the Trump administration and state officials to protect consumers from what they view as overreach by large pharmaceutical companies. The Attorney General’s office may pursue further legal remedies if Eli Lilly does not promptly cease the disputed practices.
Missouri residents, especially those in rural areas, are encouraged to stay informed about their rights under the 340B program and to report any pricing concerns to the Attorney General’s office.
Original reporting: KY3 Springfield (local) — read the source article.
